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Takashi Mizuno (1931-2000) 
Professor Emeritus of Shizuoka University 
 
This article is written in memory of Professor Takashi 
Mizuno who died in May 2000. He had focused a lifetime 
of research upon development of various antitumor 
substances from medicinal mushrooms, and is considered 
one of the 20th century greatest scientist in his field. 
Mizuno proved that many polysaccharides with antitumor 
and immunopotentiating qualities were synthesised in 
cultured mycelia no less and in fact often better than in 
fruiting bodies. This result virtually revolutionised 
mushroom producing and processing business.  
“Medicine and food both originate from the same root” is 
a Japanese proverb Mizuno often quoted. 
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Anti-tumor activity of mushroom fruit bodies and mycelial extracts evaluated using different cancer cell 
lines. These polysaccharide extracts showed potent antitumor activity against sarcoma 180, mammary 
adenocarcinoma 755, leukemia L-1210 and a host of other tumors. The antitumor activity was mainly 
due to indirect host mediated immunotherapeutic effect. These studies are still in progress in many 
laboratories and the role of the polysaccharides as immunopotentiators is especially under intense 
debate. The purpose of the present review is to summarize the available information in this area and to 
indicate the present status of the research. 
 





The global awareness of cancer as the second largest 
cause of death in people of various ages and racial 
background has lead to so much research efforts and 
clinical  studies  in  the  fight  against  the   disease.   The  
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prevention of cancer by the ingestion of chemical agents 
aimed at minimizing the risk of carcinogenesis has 
greatly reduced the morbidity and mortality rates. These 
agents include non-steroid anti-inflammatory drugs 
(NSAID) such as aspirin, sulindac, piroxican and 
indomethacin, which inhibit cyclooxygenase (COX). 
Cyclooxygenase inhibition is necessary because it 
catalyzes the conversion of arachidonic acid to pro-
inflammatory substances such as prostaglandin, which 
can stimulate growth of tumor cells and suppress immune 
surveillance. It also activates carcinogens to take up 
forms that damage the genetic material ((Jang et al., 





The curious question, which everyone asks, is “ what 
really causes cancer.” The immediate response from 
most people will be tobacco smoking, alcohol 
consumption, excess use of caffeine and other drugs, 
sunshine, infection from such oncogenic virus like 
cervical papillomaviruses, adenoviruses Karposis 
sarcoma (HSV) or exposure to asbestos. These 
obviously are implicated as causal agents of mammalian 
cancers. However a large population of people are often 
exposed to these agents with only very few being 
affected which tell us that these may not really be the root 
cause of cancer. 
Gibbs (2003) explained that the immediate cause of 
cancer must be some combination of insults and 
accidents that induce normal cells in a healthy human 
body to turn malignant, growing uncontrollably in 
unnatural places. The elucidation of DNA as the genetic 
material ushered in the era of molecular genetics and 
cancer is now seen as a result of cumulative mutations 
that alter specific locations in a cell’s DNA and thus 
change the particular protein encoded by cancer–related 
genes at those locations. These mutations affect two 
kinds of cancer genes namely: tumor suppressors and 
oncogenes. Tumor suppressors normally restrain the 
cell’s ability to divide and mutations on this gene render it 
inactive. Oncogenes on the other hand stimulate cell 
growth and cell division. Mutations on the oncogenes 
make them permanently active thus promoting cell 
growth and progressive changes leading to the increase 
of the cancer genes (Gibbs, 2003).  Consequently cancer 
cells continue to divide even in situations in which normal 
cells will usually wait for a special chemical transduction 
signal. The tumor cells would ignore such stop signals 
that are sent out by adjacent tissues. Cancer cells also 
have the character of immortality even in vitro whereas 
normal cells stop dividing after 50-70 generations and 
undergoes a programmed cell death (Apoptosis). Cancer 
cells continue to grow invading nearby tissues and 
metastasizing to distant parts of the body. Metastasis is 
the most lethal aspect of carcinogenesis. The 
phenomena is such that before a tumor is discovered and 
removed by surgery a few cells of the tumor would 
detach from the initial mass, float through the circulation 
system and start a new colony in a different organ from 
the one that gave birth to it.  
The theory that cancer results from cumulative 
mutations that alter specific genes in the DNA has come 
under great challenge recently. Biologists now trace the 
cause of tumor to include other abnormalities at work 
inside the cell nucleus that though not yet malignant is 
prone to become so. Recent hypotheses advanced to 
challenge the earlier one include the hypothesis that a 
breakdown in DNA duplication or repair leads to many 
thousands of random mutations in cells. Secondly that 
damage to a few “master” genes mangles the 
chromosomes, which then becomes dangerous, plunging 
the cells into a ploidal confusion and  chaos.  Finally  that  




the abnormal number of chromosomes in a cell may be 
the milestone on the road to cancer (Gibbs, 2003). 
However, there is great expectation that one day science 
will produce a definitive answer to the root cause of 
cancer. It may probably be a very complicated answer or 
a simple one, which may force us to shift our hope from 
curative drugs to chemopreventives. 
 It has been difficult to develop specific remedies 
against cancer as with the development of vaccine 
against viral infections and antibiotics. Cancer cells 
originate from normal cells and a novel drug able to 
select and destroy only affected cells preventing 
carcinogenesis without injury to normal cell would be an 
ideal chemotherapy against cancer. This is a very difficult 
task facing cancer researchers. Recent investigations 
has been channeled on the development of 
immunotherapy to target and remove cancer cells as well 
as on substances such as immunopotentiators, 
immunoinitiators and biological response modulators 
(BRM) that act to prevent carcinogenesis and induce 
carcinostasis (Wasser and Weis, 1999). 
Mushrooms belong to this group of immunoceuticals by 
their mode of action. The use of medicinal mushrooms in 
the fight against cancer is known for a very long time in 
Korea, China, Japan, Russia, USA and Canada. An old 
Japanese legend reports that wild monkeys rarely 
experience cancer, high blood pressure, or diabetes. The 
legend suggests that perhaps it is due to some extent 
their consumption of wild mushrooms. This legend in 
Japan may have help spur research into the role of 
mushroom in medicine. These mushrooms belonging to 
the family Polyporaceae have been effective against 
esophageal, stomach, prostate and lung cancers. Lucas 
et al.  (1957) demonstrated the anti-tumor effect of higher 
basidiomyces (specifically extracts of fruiting bodies of 
Boletus edulis). Yohida et al. in 1962 isolated from 
Lampteromyces japonicus (kowamura) Sing, an agent 
active against Ehrlich carcinoma of the mouse. Gregory 
(1966) experimented on more than 7000 cultures of 
higher basidiomyces for anti-tumor activity against rodent 
tumor systems. Positive inhibitory effects were obtained 
using fermentation media materials against sarcoma 180, 
mammary adenocarcinoma 755, and leukemia L-1210. 
Ikegawa et al.  (1968) reported that an essence obtained 
from the fruit body of edible mushrooms exhibited 
remarkable host-mediatory anti-tumor activity against 
grafted cancer in animals such as sarcoma 180. Daba 
(1998) and Daba et al. (2002) reported that Pleurotus 
ostreatus mushrooms cultivated on date waste posses a 
potent antitumor activity against Ehrlich ascites 
carcinoma. Further biochemical studies were carried out 
by the authors on the effect of mushrooms and isolated 
polysaccharides on the tumors transplanted in mice. The 
anti-tumor essence was later discovered to be a type of 
β-D-glucan, a polysaccharide yielding D-glucose only by 
acid hydrolysis (Mizuno, 1999). β-D-glucan has a 
different    mode    of    action    from    the    conventional  




chemotherapeutic agents in that it is immunotherapeutic. 
Inhibiting the growth of cancer cells by activating and 
reinforcing the host immune system. This present review 
elucidates the anti-tumor polysaccharides from 
mushrooms, their chemical structures, results obtained 




COMPOSITION OF MUSHROOM ANTITUMOR 
POLYSACCHARIDES 
 
Polysaccharides are polymers of sugars 
(monosaccharides) joined to each other by glycosidic 
linkages. These are very complex molecules because 
sometimes covalent bonds occur between many pairs of 
carbon atoms. Consequently one sugar unit can be 
joined to more than two other sugars, which results in the 
formation of highly branched enormous macromolecules. 
Polysaccharides are a structurally diverse class of 
macromolecules able to offer the highest capacity for 
carrying biological information due to a high potential for 
structural variability (Wasser, 2002). Whereas the 
nucleotides and amino acids in nucleic acids and proteins 
effectively, interconnect in only one way, the 
monosaccharide units in polysaccharides can 
interconnect at several points to form a wide variety of 
branched or linear structures  (Sharon and Lis, 1993). 
This high potential for structural variability in 
polysaccharides gives the necessary flexibility to the 
precise regulatory mechanisms of various cell-cell 
interactions in higher organisms. The polysaccharides of 
mushrooms occur mostly as glucans. Some of which are 
linked by β-(1-3), (1-6) glycosidic bonds and α-(1-3) 
glycosidic bonds but many are true heteroglycans.  
Most often there is a main chain, which is either β(1-3), 
β(1-4) or mixed β(1-3), β(1-4) with β(1-6) side chains. 
Hetero-β-D-glucans, which are linear polymers of glucose 
with other D-monosaccharides, can have anticancer 
activity but α-D-glucans from mushroom usually lack 
anticancer activity (Wasser, 2002). Heteroglucan side 
chains contain glucuronic acid, galactose, mannose, 
arabinose or xylose as a main component or in different 
combinations. Glycans are polysaccharides containing 
units other than glucose in their backbone. A wide range 
of antitumor or immunostimulating polysaccharides of 
different chemical structure from higher Basidiomyces 
mushrooms has been investigated (Wasser, 2002). Some 
correlation has been drawn between the chemical 
structure and antitumor activities of mushroom 
polysaccharides. A wide range of glycans extending from 
homopolymers to highly complex heteropolymers (Ooi 
and Liu, 1999) exhibits antitumor activity. Differences in 
activity can all be correlated with ability of the 
polysaccharide molecule to solubilize in water, size of the 
molecules, branching rate and form. Such structural 





of the glucan and additional β-(1-6)-branch points are 
needed for antitumor activity (Wasser, 2002). β-glucans 
with only (1-6) glycosidic linkages have little or no activity. 
Higher molecular weight glucans have been reported by 
Mizuno et al.  (1996) and Mizuno (1999) to be more 
effective than those of low molecular weight against 
tumors. 
There is a broad similarity in the various methods that 
have been developed for extraction of anti-cancer 
polysaccharides from mushrooms. Usually dried 
mushroom in powdered form is heated in 80% ethanol to 
eliminate low molecular weight substances. Crude 
fractions are obtained from the remaining ethanol 
extracts by further extraction with water, 1% ammonium 
oxalate and 5% sodium hydroxide. The polysaccharides 
are then fractionally purified by a combination of 
techniques, including ethanol concentration, fractional 
precipitation, ion-exchange chromatography, gel filtration 
and affinity chromatography. A recent study by Yap and 
Ng (2001) has established a more efficient procedure for 
the extraction of β-glucan from mushroom. The β-glucan 
is isolated through ethanol precipitation and freeze-dried 
in liquid nitrogen. Purity testing using a carbohydrate 
analysis column produced 87.65% purity.  
 
 
MUSHROOMS POLYSACCHARIDES IN THE 
TREATMENT OF CANCER 
 
Immunoceuticals are substances having 
immunotherapeutic efficacy when administered orally. 
More than 50 mushrooms species have yielded potential 
immunoceuticals that exhibit anticancer activity invitro or 
in animal models. Six of these polysaccharides that have 
been investigated in human cancers include Lentinan, 
Schizophyllan, Active hexose correlated compounds 






Lentinan, produced from Shiitake mushroom, Lentinus 
edodes, is a β(1-3), β(1-6) glucan. There is an immense 
literature related to the anticancer effect of lentinan on 
animals and human carcinomas. It was first isolated and 
studied by Chihara et al.  (1970) who demonstrated that 
its antitumor effects were greater than other mushroom 
polysaccharides. Maeda et al.  (1974) however reported 
that lentinan was active for some but not all types of 
tumors. There have been numerous clinical trials of 
lentinan in Japan, and the drug is now manufactured and 
sold by several pharmaceutical companies. 
Lentinan has proved successful in prolonging the 
overall survival of cancer patients, especially those with 
gastric and colorectal carcinomas (Furue et al., 1981 





cancer, tumor responses and prolonged median survival 
were also noted. In a randomized controlled study of 
patients treated with tegafur or a combination of lentinan 
and tegafur overall survival was significantly prolonged in 
the lentinan plus tegafur group. Overall more patients 
with the combined therapy appeared to survive longer: 
19.5% survived more than one year 10.4% more than two 
years and 6.5% more than three years. Using the criteria 
of the Japan society for cancer therapy for evaluation of 
clinical effects of cancer chemotherapy on solid tumours, 
patients treated with lentinan had a significantly higher 
response rate (14.9% than patients in the control arm. 
Few adverse reactions to lentinan have been noted. In 
a detailed study of 469 patients, 32 (6.8%) experienced 
an adverse reaction, only 2 patients required 
discontinuation of treatment due to unacceptable 
tolerance. Perhaps the most intriguing aspects of lentinan 
use in conjunction with other chemotherapeutic agents is 
its apparent ability to greatly reduce the debilitating 
effects of the chemotherapy, e.g. nausea, pain, hair loss 





This polysaccharide derived from the mushroom 
Schizophyllum commune has been shown to be 
cytostatic in sarcoma 180 tumor xenographs. The 
survival of these xenographs was not affected by 
pretreatment with schizophyllan. Schizophyllan had no 
effect on the survival of sarcoma 37, Ehrlich carcinoma or 
Yoshida sarcoma ascites tumors (Wasser and Weis, 
1999). 
Various clinical trials have been carried out in Japan, 
although many are not blinded. Despite this schizophyllan 
has been approved for clinical use in Japan. Early clinical 
studies with schizophyllan in combination with 
conventional chemotherapy (tegafur or mitomycin C and 
5-fluorouracil) in a randomized controlled study of 367 
patients with recurrent and inoperable gastric cancer 
resulted in a significant increase in median survival 
(Furne, 1985). However, a similar study was unable to 
confirm this apparent success with schizophyllan 
(Fuginoto et al., 1984). Recently schizophyllan has also 
been shown to increase overall survival of patients with 
head and neck cancers (Kimura et al., 1994). In a 
randomized controlled study of schizophyllan in 
combination with radiotherapy, schizophyllan significantly 
prolonged the overall survival of stage II cervical cancer 
patients but not stage III (Okamura et al., 1986, 1989). In 
a prospective, randomized clinical trial involving 312 
patients treated with surgery, radiotherapy, 
chemotherapy (fluorouracil) and schizophyllan in various 
combinations, patients treated with schizophyllan had a 
better overall survival than patients who had not received 
the polysaccharides (Miyazaki et al., 1995).  
Schizophyllan is currently produced commercially by 
several Japanese pharmaceutical companies. 




Active Hexose correlated compound (AHCC) 
 
AHCC is a proprietary extract prepared from co-cultured 
mycelia of several species of basidiomycete mushrooms, 
including Shiitake (Lentinus edodes). Animal research 
and preliminary human studies indicated AHCC has 
anticancer efficacy. Beginning in 1992, Kamiyama 
conducted a trial in Japan to evaluate the preventive 
effect of AHCC against recurrence of hepatocellular 
carcinoma following surgical resection. The investigators 
reported that after one year the AHCC group showed a 
significant higher survival rate than the control group, as 
well as significant lowering of certain tumor markers in 
the serum. The AHCC Research Association was formed 
in Japan in 1996 to foster the development of AHCC as 
an anticancer therapy. In their circulating abstracts they 
report that of 300 cancer patients administered AHCC, 58 
were effectively treated, with 46 showing complete or 
partial regression and 12 experiencing no change of 





Several studies have shown that B-D-glucan derived from 
Grifola frondosa (also known as Maitake) have strong 
antitumor activity in xenographs (Kurashiga et al., 1997) 
and there have also been limited number of clinical trials. 
More recently, a highly purified extract, β-glucan (B-1,6 
glucan branched with a β 1-3-linkage) (Grifron-D, GD) 
has become available. GD has considerable 
immunomodulating and antitumor activities in animal 
models, and is orally bioavailable (Nishida et al., 1988). 
Maitake D-fraction and crude Maitake powder have 
demonstrated remarkable inhibition of metastasis in a 
mouse model, especially in the prevention of hepatic 
metastases, which in one series of experiments was 
reduced by 81% (Maitake powder) to 91% (D-fraction) 
(Nanba, 1995). GD has been shown to have a cytotoxic 
affect on human prostate cancer cells (PC9) in vitro, 
possibly acting through oxidative stress, and causing 
95% cell death by an apoptosis (Fullerton et al., 2000). 
Vitamin C addition reduced the effective level of GD 
required. 
Jones (1998) reported an early pilot study from China 
involving 63 cancer patients which showed a response 
rate (partial and complete) against solid tumour at 95% 
and for leukaemia 90%. Nanba (1997) observed tumour 
regression or significant symptomatic improvement in 11 
out of 15 hepatocellular carcinomas with D-fraction plus 
Maitake. When D-fraction plus Maitake was combined 
with chemotherapy, the overall response rates were 
increased by 12-28% when results from cancer types 
were combined. The Food and Drug Administrarion 
(USA) has approved Grifon-D (GD) for trial under an 
Investigational New Drug Application (IND) for patients 
with advanced cancer and some US-based  clinical  trials  








Development of carcinostatic drugs  
 
Three polysaccharide based carcinostatic (immunotherap 
eutic) agents, Krestin, Lentinan and Sonifilan, have 
already been developed from mushroom. These are used 
currently in the treatment of cancer of the digestive 
organs, lung and breast, as well as cancer of the 
stomach and cervical cancer respectively. Several 
mushroom species belonging to the polyporaceae family 
are now regarded as the next drug producers. Mushroom 
polysaccharides are also expected to be developed into 
multipurpose medicines that are not only carcinostatic but 
also anti-inflammatory, antiviral (against AIDS), 
hypoglycaemic and antithrombotic. 
 
 
MECHANISM OF ACTION OF MUSHROOM 
POLYSACCHARIDES  
 
The Egyptians as far back as 3000 BC believed that 
mushroom were a sacred food that prolonged life. A 
mummified 5000-year old “Ice-man” found in the 
mountains of Europe carried a medicine kit of dried 
mushrooms. Indeed the oldest written record of 
mushrooms as medicines is in Indian medical treatise 
from 3000BC (Kual, 1997). Of significant relevance and 
importance is the ability of particular mushrooms-derived 
compounds to modulate the human immune response 
and to inhibit certain tumour growths (Wesser and Weis, 
1999a, 1999b). Medicinal mushroom research has 
focused on discovery of compounds that can modulate 
positively or negatively the biologic response of immune 
cells. Those compounds, which appear to stimulate the 
human immune response, are being sought for the 
treatment of cancer, immunodeficiency disease or for 
generalised immunosuppression following drug 
treatment. They are also sought for combination therapy 
with antibiotics and as adjuncts for vaccines (Jang et al., 
1997). Wasser (2002) reported that mushroom 
polysaccharides are regarded as biological response 
modifiers (BRM). This basically means that they cause no 
harm and place no additional stress on the body, but help 
the body to adapt to various environmental and biological 
stresses. Mushroom polysaccharides support some or all 
of the major systems of the body, including nervous, 
hormonal and immune systems as well as regulatory 
functions. The polysaccharides from mushrooms do not 
attack cancer cells directly, but produce their antitumour 
effects by activating different immune response in the 
host (Wasser, 2002).  
Hobbs (2000) reported that L. edodes produces two 
bioactive preparations, which are efficient immune 





bioactive polymers appear to act as host defence 
potentiators restoring and enhancing the responsiveness 
of host cells to lymphocytokines, hormone and other 
biologically active substances. The immunopotentiation 
has been shown to occur by stimulating the maturation, 
differentiation or proliferation of cells involved in host 
defence mechanism. Chihara et al.  (1998, 1992) 
reported that Lentinan increase host’s resistance against 
various kinds of cancer and has the potential to restore 
the immune function of affected subjects. Many of these 
pathways stimulated by Lentinan are illustrated by 
Chihara et al.  (1999) (Figure 1). The interaction of 
Lentinan with many kinds of immune cells was not known 
until recently. Ross et al.  (1999) provided an insight into 
receptor binding in immune cells by β-glucan from fungi 
and further showed that β-glucan from yeast bind to iC3b-
receptors (CR3, CD11b/CD18) of phagocytic and natural 
killer (NK) cells. When this happens, it will stimulate 
phagocytosis and/or cytotoxic degranulation. Lentinan 
has also been shown to stimulate peripheral blood 
lymphocytes in vitro to increase interleukin-2-mediated 
LAK cell (lymphokine-activated killer cell) and NK cell 
activity at levels achievable in vivo by administration of 
clinical doses of Lentinan. This observation was made 
using the blood of healthy donors and cancer patients. 
Lentinan has also been shown to inhibit suppressor T 
cells activity in vivo and to increase the ratio of activated 
T cells and cytotoxic T cells in the spleen when 
administered to gastric cancer patients undergoing 
chemotherapy. Many interesting biological activities of 
Lentinan including increase in the activation of non-
specific inflammatory response such as acute phase 
protein production (Suga et al., 1986); vascular dilation 
and haemorrhage-inducing factor in vivo (Maeda et al., 
1991), activation and generation of helper and cytotoxic T 





Mushroom polysaccharides offer a lot of hope for cancer 
patients and sufferers of many devastating diseases. A 
fundamental principle in oriental medicine is to regulate 
homeostasis of the whole body and to bring the disease 
person to his or her normal state  (Chihara et al., 1992). 
Potentiation of the physiological constitution in favour of 
host defence results in the activation of many vitally 
important cells for the maintenance of homeostasis. A 
variety of polysaccharides from a number of mushroom 
varieties have been demonstrated to enhance the 
immune system. All of these have shown significant 
antitumour activity as a result of their ability to activate 
the host immune system rather than direct cytotoxicity. 
The mushroom polysaccharides appear to be well 
tolerated and compatible with chemotherapy and 
radiation therapy. However, studies that identifies the 
molecular  mechanisms  that  occur  in  specific   immune  















































     Figure 1. Host immune response involved in Lentinan-mediated destruction of cancer cells (Chihara et al., 1992). 
 
 
modulation by mushroom polysaccharides such as 
receptors and what downstream events are triggered by 
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